Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Phase 2

Completed

• Conditions: Atrial Fibrillation
• Interventions: Drug: Capadenoson (BAY68-4986)

• Registration Number: NCT00568945
• Lead Sponsor: Bayer

Brief Summary

This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-10-25
• Study First Submitted QC: 2007-12-04
• Study First Posted: 2007-12-06
• Study Start: 2008-01
• Primary Completion: 2008-11
• Study Completion: 2008-12
• Status Verified: 2014-10
• Last Update Submitted: 2014-10-28
• Last Update Posted: 2014-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Male and/or female (without childbearing potential) white patients
• History of persistent or permanent atrial fibrillation
• 18 to 75 years of age

Exclusion Criteria

• Patients with high-risk cardiovascular diseases
• Stroke or myocardial infarction
• Relevant pathological changes in the ECG or echocardiography
• Medication affecting ventricular response in Afib

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Arm 1	Capadenoson (BAY68-4986)	-

Primary Outcome Measures

Name	Time	Method
The effect of capadenoson (BAY68-4986) on rate control in patients with atrial fibrillation	1 week

Secondary Outcome Measures

Name	Time	Method
To investigate safety and tolerability of this treatment with capadenoson	2 weeks